Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX103 in Non-infectious Uveitis
NCT07427628Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Regulatory T Cells (Tregs), Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TRX103 in noninfectious uveitis (NIU) (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 52 weeks, Incidence of infections at 52 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
TRX103
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT07427628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07427628.